Chronic high-dose dimenhydrinate use contributing to early multifactorial cognitive impairment.
Nicholas FabianoSaumil DholakiaLisa A S WalkerAndrew L SmithPublished in: BMJ case reports (2024)
Dimenhydrinate is an over-the-counter antihistaminergic medication with anticholinergic properties used to treat nausea or motion sickness worldwide. There is a well-established correlation between the use of anticholinergic medications and dementia, however, it is unclear if a causal role exists. We report a case of minor neurocognitive disorder in a woman in her 40s with several years of high-dose daily dimenhydrinate abuse who subsequently developed significant delusional beliefs. Her clinical presentation was confounded by numerous other factors that could have impacted her cognition, such as a longstanding presumed learning disability, ankylosing spondylitis with adalimumab treatment, extensive cannabis use or potential development of a primary psychotic disorder. Her workup was within normal limits, and she has not responded to first-line antipsychotic medications to date. This case report adds to the growing evidence supporting concerns about potentially irreversible cognitive deficits in chronic misuse of anticholinergic agents, an association previously observed only in the elderly population.
Keyphrases
- high dose
- ankylosing spondylitis
- cognitive impairment
- case report
- rheumatoid arthritis
- low dose
- mild cognitive impairment
- stem cell transplantation
- bipolar disorder
- disease activity
- physical activity
- multiple sclerosis
- chronic pain
- middle aged
- emergency department
- juvenile idiopathic arthritis
- risk assessment
- white matter
- high resolution
- community dwelling
- human health
- adverse drug